Reflow™ (recombinant human TNK tissue-type plasminogen activator, rhTNK-tPA) is a new third-generation specific thrombolytic drug approved in 2015 for the treatment of acute myocardial infarction (AMI). A clinical study of Reflow™ on the indication of acute ischemic stroke (AIS) is underway.
A Phase II clinical study (TRACE) of Reflow™ (recombinant human TNK tissue-type plasminogen activator) for the treatment of acute ischemic stroke (AIS) in the hyperacute phase has been completed. As the first Phase II clinical study of TNK intravenous thrombolysis for the treatment of AIS in China, TRACE is a multicenter, randomized, open-label, blinded endpoint evaluation study, which was published in the journal Stroke and Vascular Neurology (SVN) on August 24, 2021. (Click to view the study results and redirect to the article in the News section). A Phase III clinical study of the product for the treatment of AIS is underway.
bridging thrombolysis, intra-arterial thrombolysis, and other directions, we have also cooperated with many clinical experts to initiate several IIT clinical studies. We believe that more evidence-based medicines will be generated in the future, bringing benefits to patients with cerebral infarction.
